Phase I, open label, non-randomised, non-comparative, multi-center study, evaluating S65487, a Bcl-2 inhibitor intravenously administered, in patients with Relapse or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma or Multiple Myeloma.
- Spencer, Andrew (Primary Chief Investigator (PCI))
- Kennedy, Nola (Project Manager)
Project: Research